In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.
Illumina's net-net working capital per share for the quarter that ended in Mar. 2022 was $-14.45.
The industry rank for Illumina's Net-Net Working Capital or its related term are showing as below:
Illumina Net-Net Working Capital Historical Data
The historical data trend for Illumina's Net-Net Working Capital can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
|
Illumina Annual Data
|
|
Trend |
Dec12 |
Dec13 |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
| Net-Net Working Capital |
|
|
|
|
|
|
0.76 |
6.05 |
8.98 |
7.76 |
-15.52 |
|
Illumina Quarterly Data
|
|
Jun17 |
Sep17 |
Dec17 |
Mar18 |
Jun18 |
Sep18 |
Dec18 |
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
| Net-Net Working Capital |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
9.36 |
9.43 |
-16.25 |
-15.52 |
-14.45 |
Competitive Comparison
For the Diagnostics & Research subindustry, Illumina's Net-Net Working Capital, along with its competitors' market caps and Net-Net Working Capital data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Illumina Net-Net Working Capital Distribution
For the Medical Diagnostics & Research industry and Healthcare sector, Illumina's Net-Net Working Capital distribution charts can be found below:
* The bar in red indicates where Illumina's Net-Net Working Capital falls into.
Illumina Net-Net Working Capital Calculation
Illumina's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Dec. 2021 is calculated as
Illumina's Net-Net Working Capital (NNWC) per share for the quarter that ended in Mar. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.
In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
This is a conservative way of estimating the company's value.
Illumina Business Description
Traded in Other Exchanges
Address
5200 Illumina Way, San Diego, CA, USA, 92122
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates revenue from sequencing tools and dedicated consumables (76% of 2020 sales). Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications. Services account for 16% of sales and include basic maintenance services, clinical lab applications (such as noninvasive prenatal, oncology, and rare-disease screening), and whole genome sequencing.
Executives
| Flatley Jay T |
director |
9885 TOWNE CENTRE DR SAN DIEGO CA 92121 |
| Tousi Susan H |
officer: SVP Product Development |
5200 ILLUMINA WAY SAN DIEGO CA 92122 |
| Reeves Kathryne Gambrell |
officer: SVP, Chief Marketing Officer |
5200 ILLUMINA WAY SAN DIEGO CA 92122 |
| Goswami Joydeep |
officer: SVP Corp Business Development |
SUMITOMO FUDOSAN MITA TWIN BLDG EAST WING 4-2-8 SHIBAURA MINATO-KU TOKYO M0 1080023 |
| Dadswell Charles |
officer: SVP & General Counsel |
5200 ILLUMINA WAY SAN DIEGO CA 92122 |
| Desouza Francis A |
director, officer: President and CEO |
350 ELLIS STREET MOUNTAIN VIEW CA 94043 |
| Van Oene Mark |
officer: SVP Chief Commercial Officer |
5200 ILLUMINA WAY SAN DIEGO CA 92122 |
| Ragusa Robert P |
officer: SVP, Global Quality & Ops |
PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: RAGUSA ROBERT P a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;} |
| Mcginnis Karen K |
officer: VP, Chief Accounting Officer |
INSIGHT ENTERPRISES INC 1305 WEST AUTO DRIVE TEMPE AZ 85284 |
| Hoyt Aimee L |
officer: SVP, Chief People Officer |
5200 ILLUMINA WAY SAN DIEGO CA 92122 |
| Ronaghi Mostafa |
officer: SVP, Entrepreneurial Devlopmt |
9885 TOWNE CENTRE DRIVE SAN DIEGO CA 92121 |
| Aravanis Alexander |
officer: SVP, Chief Technology Officer |
5200 ILLUMINA WAY SAN DIEGO CA 92122 |
| Siegel Susan E |
director |
3000 SAND HILL ROAD BLDG 3 STE 290 MENLO PARK CA 94025 |
| Thompson John Wendell |
director |
C/O MICROSOFT CORPORATION ONE MICROSOFT WAY REDMOND WA 98053 |
| Epstein Robert S |
director |
PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: EPSTEIN ROBERT S a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;} |
Illumina Headlines
By Seekingalpha 2022-03-07
By Seekingalpha 2022-02-10
By tipranks.com 2022-03-02
By Seekingalpha 2022-01-10
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
5.57(2.27%) Volume: 234,144 11:14AM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:ILMN has been successfully added to your 